Targeting a specific cell death process in aggressive prostate cancer
Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer
['FUNDING_R01'] · DUKE UNIVERSITY · NIH-11052646
This study is looking at how a certain change in prostate cancer cells makes them easier to kill with a special type of cell death, and it's hoping to find new drug treatments that could help patients with advanced prostate cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11052646 on ClinicalTrials.gov |
What this research studies
This research investigates how a specific genetic alteration in prostate cancer cells makes them more susceptible to a type of cell death known as ferroptosis. By understanding the mechanisms behind this vulnerability, the researchers aim to develop new drug therapies that can effectively target and kill these cancer cells. The study involves preclinical testing of drug combinations that could enhance the effectiveness of ferroptosis in treating late-stage prostate cancer. Patients may benefit from innovative treatment options that arise from these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer, particularly those with RB1 genetic alterations.
Not a fit: Patients with early-stage prostate cancer or those without RB1 genetic alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates for men with aggressive prostate cancer.
How similar studies have performed: Other research has shown promising results in targeting ferroptosis in various cancer types, suggesting potential for success in this novel approach.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, MING — DUKE UNIVERSITY
- Study coordinator: CHEN, MING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer